{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/luts-in-men/prescribing-information/alpha-blockers/","result":{"pageContext":{"chapter":{"id":"9c9f3458-4ae7-5003-a4f9-ed026a61a3d0","slug":"alpha-blockers","fullItemName":"Alpha-blockers","depth":2,"htmlHeader":"<!-- begin field de880639-53b7-4581-b4d4-013e08dfdbc1 --><h2>Alpha-blockers</h2><!-- end field de880639-53b7-4581-b4d4-013e08dfdbc1 -->","summary":"","htmlStringContent":"<!-- begin item b92bced3-79cc-4891-9d37-8704548181fa --><!-- end item b92bced3-79cc-4891-9d37-8704548181fa -->","topic":{"id":"fdcce69d-578e-5994-a7c2-84be40932dd8","topicId":"a7bf3f2d-1d9e-47c0-9dd3-26731c4d092b","topicName":"LUTS in men","slug":"luts-in-men","lastRevised":"Last revised in March 2019","chapters":[{"id":"149361eb-636f-59a5-a2e2-b067d629a065","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"c7972342-637c-56a9-8783-c1e8314e7fd1","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7105be47-f38b-5335-b14d-69db43326579","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"c8165ab8-59af-557d-824d-58f09041698f","slug":"changes","fullItemName":"Changes"},{"id":"776566d2-009e-5ebd-ac21-e5605029213a","slug":"update","fullItemName":"Update"}]},{"id":"4c1332b1-3f4f-530f-bb70-d627804caa79","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d434ba09-30c6-5bfc-bb6f-87e952a1b33a","slug":"goals","fullItemName":"Goals"},{"id":"702b01d3-71e8-5daf-a985-3935596391f5","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0aef110d-14b4-5ae2-9da0-a07cc4aef9ef","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7fcf6ae7-162e-5b90-84fb-2a79f82d420e","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1c91c138-4e44-571e-8ac0-8e62f8dca310","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"4fe99a13-4e80-5c28-b091-216c8a8d7f82","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"3a98397f-2bc4-5e01-90d6-03d6fbe400c8","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"d41a85e2-c1cb-5198-afc7-7c4fbe28ae24","slug":"definitions","fullItemName":"Definitions"},{"id":"fd0f4942-31d6-517a-a10b-d341e34a2504","slug":"causes-of-luts","fullItemName":"Causes of LUTS"},{"id":"3af3e2a4-26b3-5a77-9e8b-3d393388e624","slug":"prevalence","fullItemName":"Prevalence"},{"id":"1c6eecc6-b753-5918-adae-dc2d864d88fa","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"d1432aa0-7841-5eec-85c4-e344d4629bd9","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"762c13bd-ead4-5aa6-b460-701b0572f9aa","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8874a841-31e1-5356-a3f6-7bff9c28c693","slug":"assessment","fullItemName":"Assessment"},{"id":"8c77fb91-6134-565b-b1ef-4452e83c424f","slug":"investigations","fullItemName":"Investigations"}]},{"id":"60ffa7b7-da40-599a-bffa-e6e68db76a97","fullItemName":"Management","slug":"management","subChapters":[{"id":"1d790431-a0c8-5ca1-8143-be639ea2ec02","slug":"voiding-symptoms","fullItemName":"Scenario: Voiding symptoms"},{"id":"b1451e1b-3776-5aa0-94b0-79be5fb01831","slug":"overactive-bladder","fullItemName":"Scenario: Overactive bladder"},{"id":"f4818005-dc3a-52b2-ac5d-d14f0d6ac0db","slug":"nocturnal-polyuria","fullItemName":"Scenario: Nocturnal polyuria"},{"id":"fb3acb54-4d76-5aad-ab1c-7b0b3d9443a3","slug":"stress-urinary-incontinence","fullItemName":"Scenario: Stress urinary incontinence"},{"id":"c511bb10-1198-548d-8e23-a1f6e98df926","slug":"urinary-retention","fullItemName":"Scenario: Urinary retention"},{"id":"0a3e83b8-a00f-520f-b21f-9ef6cc6440e7","slug":"post-micturition-dribble","fullItemName":"Scenario: Post-micturition dribble"}]},{"id":"40ed844e-b196-5a8a-9d88-2ff299e04d85","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"9c9f3458-4ae7-5003-a4f9-ed026a61a3d0","slug":"alpha-blockers","fullItemName":"Alpha-blockers"},{"id":"2f32bd76-64d1-51c9-bc96-4173829de1b5","slug":"5-alpha-reductase-inhibitors","fullItemName":"5-alpha reductase inhibitors"},{"id":"d7f3eec1-9124-5d3a-a793-15707f8cfeda","slug":"antimuscarinics","fullItemName":"Antimuscarinics"},{"id":"507e078b-b3d0-527c-b71d-0b1101948c01","slug":"mirabegron","fullItemName":"Mirabegron"},{"id":"7c2851da-6e40-5415-ada7-7466766510fa","slug":"furosemide","fullItemName":"Furosemide"},{"id":"ae12d520-87b4-5400-8cfa-79a25bb39663","slug":"desmopressin","fullItemName":"Desmopressin"}]},{"id":"dca797b5-427f-5ed5-94e4-3ad565f628a9","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5e289c42-8089-5739-9683-20c374967578","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"07accac1-c375-54a3-92cc-d2cd8a2bb914","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c05a5332-4c79-595e-b066-09dcd9841073","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"8e5cf2cc-d3d4-5d7d-82a7-3dd1ae3c65d9","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"47ea76bd-52d3-5c5a-8d1f-f574eec081bd","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"38a45d79-a74f-5ca9-a844-f16ea2c0ab75","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0b3152db-f873-5814-b35f-54711f247dff","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"40ed844e-b196-5a8a-9d88-2ff299e04d85","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"6d6ca461-ec0f-59b9-bda1-14b0009c9037","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 7535a0ed-6e13-4305-8ab2-3b38976e2cc3 --><h3>What are the contraindications and cautions for alpha-blockers?</h3><!-- end field 7535a0ed-6e13-4305-8ab2-3b38976e2cc3 -->","summary":"","htmlStringContent":"<!-- begin item 041dd2c3-c388-494a-b8b3-a1b963eeeb63 --><!-- begin field 3f05cafc-415d-4dc6-ba0c-770670ac33cb --><h4>Alfuzosin</h4><ul><li><strong>Do not prescribe a</strong><strong>lfuzosin </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>]<strong>:</strong><ul><li>In people with:<ul><li>A history of postural hypotension.</li><li>A history of micturition syncope.</li><li>Severe hepatic impairment.</li></ul></li></ul></li><li><strong>In addition, do not prescribe alfuzosin modified-release preparations </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>]<strong>:</strong><ul><li>In people with:<ul><li>Severe renal impairment (estimated glomerular filtration rate [eGFR] less than 30 mL/minute/1.73 m<sup>2</sup>).</li><li>Hepatic impairment.</li></ul></li></ul></li><li><strong>Prescribe </strong><strong>a</strong><strong>lfuzosin</strong><strong> with cau</strong><strong>tion </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>]<strong>:</strong><ul><li>In people with:<ul><li>Acute heart failure.</li><li>History of QT-interval prolongation.</li><li>Mild to moderate hepatic impairment (for immediate-release preparations) — see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/luts-in-men/prescribing-information/alpha-blockers/#dose-initiation-titration\">Doses</a> for recommended dosage adjustments in people with hepatic impairment.</li><li>Renal impairment (for immediate-release preparations) — see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/luts-in-men/prescribing-information/alpha-blockers/#dose-initiation-titration\">Doses</a> for recommended dosage adjustments in people with renal impairment.</li></ul></li><li>After cataract surgery (risk of intra-operative floppy iris syndrome).</li><li>In elderly people.</li></ul></li></ul><h4>Doxazosin</h4><ul><li><strong>Do not prescribe </strong><strong>doxazosin </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2019a</a>]<strong>:</strong><ul><li>In people with:<ul><li>History of micturition syncope (in men with benign prostatic hypertrophy [BPH]).</li><li>History of postural hypotension.</li><li>Severe hepatic impairment.</li></ul></li><li>As monotherapy in men with overflow bladder or anuria.</li></ul></li><li><strong>Do not prescribe </strong><strong>doxazosin</strong> <strong>modified-release tablets </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2019b</a>]<strong>:</strong><ul><li>In people with gastrointestinal obstruction, oesophageal obstruction, or any degree of stricture — the outer membrane of the formulation is not digested</li></ul></li><li><strong>Prescribe doxazosin with caution </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2019a</a>]<strong>:</strong><ul><li>In people with:<ul><li>Heart failure.</li><li>Pulmonary oedema due to aortic or mitral stenosis.</li><li>Mild to moderate hepatic impairment.</li></ul></li><li>After cataract surgery (risk of intra-operative floppy iris syndrome).</li><li>In elderly people.</li></ul></li></ul><h4>Tamsulosin</h4><ul><li><strong>Do not prescribe </strong><strong>tamsulosin </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>]<strong>:</strong><ul><li>In people with:</li><li>Severe hepatic impairment.</li><li>History of postural hypotension.</li><li>History of micturition syncope.</li></ul></li><li><strong>Prescribe </strong><strong>tamsulosin with cau</strong><strong>tion </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>]<strong>:</strong><ul><li>In people with severe renal impairment (eGFR less than 30 mL/minute/1.73 m<sup>2</sup>).</li><li>After cataract surgery (risk of intra-operative floppy iris syndrome).</li><li>In elderly people.</li></ul></li></ul><h4>Terazosin</h4><ul><li><strong>Do not prescribe terazosin </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>]<strong>:</strong><ul><li>In people with:<ul><li>History of micturition syncope (in BPH).</li><li>History of postural hypotension (in BPH).</li><li>Severe hepatic impairment.</li></ul></li></ul></li><li><strong>Prescribe terazosin with caution </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>]<strong>:</strong><ul><li>In people with mild to moderate hepatic impairment.</li><li>After cataract surgery (risk of intra-operative floppy iris syndrome).</li><li>In elderly people.</li></ul></li></ul><!-- end field 3f05cafc-415d-4dc6-ba0c-770670ac33cb --><!-- end item 041dd2c3-c388-494a-b8b3-a1b963eeeb63 -->","subChapters":[]},{"id":"7b6ed6b8-b4b4-5965-85c8-dd06c891d837","slug":"dose-initiation-titration","fullItemName":"Dose - initiation and titration","depth":3,"htmlHeader":"<!-- begin field 6da2e7f0-68c2-41b9-832d-4f28a3d324b1 --><h3>How should I start and titrate an alpha-blocker?</h3><!-- end field 6da2e7f0-68c2-41b9-832d-4f28a3d324b1 -->","summary":"","htmlStringContent":"<!-- begin item 8887b5e4-0f1e-4302-a65d-975b35f543c1 --><!-- begin field b0425459-f4c6-40ec-bcb5-1b8a436e1609 --><ul><li><strong>The recommended doses are:</strong><ul><li><strong>Alfuzosin immediate-release preparations </strong>(for benign prostatic hyperplasia [BPH]) — 2.5 mg three times a day; maximum 10 mg a day.<ul><li>In elderly people, prescribe 2.5 mg twice daily initially, then adjust according to response; maximum 10 mg a day.</li><li>In mild to moderate hepatic impairment, prescribe 2.5 mg once daily, increased to 2.5 mg twice daily according to response; avoid in severe hepatic impairment.</li><li>In renal impairment, prescribe 2.5 mg twice daily and adjust according to response.</li></ul></li><li><strong>Alfuzosin modified-release preparations </strong>(for BPH) — 10 mg once daily.<ul><li>Avoid in hepatic impairment and in people with severe renal impairment (estimated glomerular filtration rate [eGFR] less than 30 mL/minute/1.73 m<sup>2</sup>).</li></ul></li><li><strong>Alfuzosin modified-release preparations </strong>(for acute urinary retention associated with BPH) — 10 mg once daily for 2–3 days during catheterization and for one day after removal; maximum of 4 days' treatment.<ul><li>Avoid in hepatic impairment and in people with severe renal impairment (eGFR less than 30 mL/minute/1.73 m<sup>2</sup>).</li></ul></li><li><strong>Doxazosin immediate-release preparations </strong>(for BPH) — initially 1 mg daily, dose may be doubled at intervals of 1–2 weeks according to response; usual maintenance dose is 2–4 mg daily; maximum 8 mg a day.<ul><li>Use with caution in mild to moderate hepatic impairment; avoid in severe impairment.</li></ul></li><li><strong>Doxazosin modified-release preparations</strong> (for BPH) — initially 4 mg once daily, dose can be adjusted after 4 weeks, then increased if necessary to 8 mg once daily.<ul><li>Use with caution in mild to moderate hepatic impairment; avoid in severe impairment.</li></ul></li><li><strong>Tamsulosin modified-release preparations </strong>(for BPH) — 400 micrograms once daily.<ul><li>Avoid in severe impairment.</li><li>Use with caution in severe renal impairment (eGFR less than 30 mL/minute/1.73 m<sup>2</sup>).</li></ul></li><li><strong>Terazosin immediate-release preparations (for BPH)</strong><ul><li>Initially 1 mg daily, taken at bedtime. If necessary dose may be doubled at intervals of 1–2 weeks according to response; maintenance 5–10 mg daily; maximum 10 mg per day.</li></ul></li></ul></li><li>More cautious titration may be needed in elderly people and in those taking <a class=\"topic-reference internal-reference\" href=\"/topics/luts-in-men/prescribing-information/alpha-blockers/#drug-interactions\">other drugs</a> with a hypotensive effect.</li><li>Use a validated scoring system (such as the <a class=\"topic-reference internal-reference\" href=\"/topics/luts-in-men/diagnosis/assessment/#international-prostate-symptom-score-ipss\">International Prostate Symptom Score</a> [IPSS] to assess and document the person's response to treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">NICE, 2015</a>].</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2019b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2019a</a>]</p><!-- end field b0425459-f4c6-40ec-bcb5-1b8a436e1609 --><!-- end item 8887b5e4-0f1e-4302-a65d-975b35f543c1 -->","subChapters":[]},{"id":"340077f4-8d32-5c00-875d-2ea92650fc2e","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 0e5d2cff-ac8e-4a35-b674-a5b971f66594 --><h3>What are the adverse effects of alpha-blockers?</h3><!-- end field 0e5d2cff-ac8e-4a35-b674-a5b971f66594 -->","summary":"","htmlStringContent":"<!-- begin item eee06dc4-15b3-4ec4-a8af-499e9c2c7eff --><!-- begin field 9c5570e0-9eec-4124-9792-61db4e9121eb --><ul><li><strong>There is a risk of first-dose hypotension and postural hypotension with alpha-blockers. </strong>Vasodilatory effects may cause a rapid reduction in blood pressure, particularly in elderly men. <ul><li>Advise the man:<ul><li>To take the first dose of standard-release alpha-blocker at bedtime.</li><li>To lie down if symptoms such as dizziness, fatigue, or sweating develop, and to remain lying down until they abate completely.</li></ul></li></ul></li><li><strong>Other adverse effects of alfuzosin include </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>]<strong>:</strong><ul><li>Common or very common — asthenia, diarrhoea, dizziness, dry mouth, headache, malaise, nausea, postural hypotension, vertigo, and vomiting.</li><li>Uncommon — abdominal pain, arrhythmias, chest pain, drowsiness, flushing, oedema, palpitations, rhinitis, skin reactions, syncope, and visual impairment.</li><li>Rare or very rare — angina pectoris and angioedema.</li><li>Frequency not known — cerebral ischaemia, floppy iris syndrome, hepatic disorders, neutropenia, priapism, and thrombocytopenia.</li></ul></li><li><strong>Other adverse effects of doxazosin include </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2019a</a>]<strong>:</strong><ul><li>Common or very common — arrhythmias, asthenia, chest pain, cough, cystitis, dizziness, drowsiness, dry mouth, dyspnoea, gastrointestinal discomfort, headache, increased risk of infection, influenza like illness, muscle complaints, nausea, oedema, pain, palpitations, skin reactions, urinary disorders, and vertigo.</li><li>Uncommon — angina pectoris, anxiety, abnormal appetite, arthralgia, constipation, depression, diarrhoea, gastrointestinal disorders, gout, haemorrhage, insomnia, myocardial infarction, abnormal sensation, sexual dysfunction, stroke, syncope, tinnitus, tremor, vomiting, and weight gain.</li><li>Rare or very rare — alopecia, bronchospasm, blurred vision, flushing, gynaecomastia, hepatic disorders, leucopenia, malaise, muscle weakness, and thrombocytopenia.</li><li>Frequency not known — floppy iris syndrome.</li></ul></li><li><strong>Other adverse effects of tamsulosin include </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>]<strong>:</strong><ul><li>Common or very common — dizziness and sexual dysfunction.</li><li>Uncommon — asthenia, constipation, diarrhoea, headache, nausea, palpitations, postural hypotension, rhinitis, skin reactions, and vomiting.</li><li>Rare or very rare — angioedema, Stevens-Johnson syndrome, and syncope.</li><li>Frequency not known — dry mouth, epistaxis, and vision disorders.</li></ul></li><li><strong>Other adverse effects of terazosin include </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>]<strong>:</strong><ul><li>Frequency not known — angioedema, anxiety, arrhythmias, arthritis, asthenia, chest pain, conjunctivitis, constipation, cough, depression, diarrhoea, dizziness, drowsiness, dry mouth, dyspnoea, epistaxis, fever, flatulence, gastrointestinal discomfort, gout, headache, hyperhidrosis, increased risk of infection, insomnia, joint disorders, myalgia, nasal congestion, nausea, oedema, pain, palpitations, paraesthesia, sexual dysfunction, skin reactions, syncope, thrombocytopenia, tinnitus, urinary disorders, vasodilation, vertigo, vision disorders, vomiting, and weight gain.</li></ul></li></ul><!-- end field 9c5570e0-9eec-4124-9792-61db4e9121eb --><!-- end item eee06dc4-15b3-4ec4-a8af-499e9c2c7eff -->","subChapters":[]},{"id":"e4a3ea80-1dd4-5d78-92b1-5e74208c30ec","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 30b35050-b0e2-4aa5-8e81-f15e513b334c --><h3>What are the key drug interactions of alpha-blockers?</h3><!-- end field 30b35050-b0e2-4aa5-8e81-f15e513b334c -->","summary":"","htmlStringContent":"<!-- begin item 4390b049-bc38-47a7-9d59-f720d6409928 --><!-- begin field 3a635b95-4489-4e7c-9279-fd175306a5c3 --><ul><li><strong>Drug interactions of alpha-blockers include:</strong><ul><li><strong>Phosphodiesterase-5 inhibitors (PDE5 inhibitor)</strong> — alpha-blockers may lead to symptomatic hypotension when given with a PDE5 inhibitor (such as sildenafil, tadalafil, or vardenafil) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">MHRA, 2009</a>].<ul><li>To minimize the risk of postural hypotension the person should be stable on the alpha-blocker before initiating a PDE5 inhibitor.</li></ul></li><li><strong>Other drugs that can cause hypotension</strong> — drugs such as angiotensin converting enzyme (ACE) inhibitors, beta-blockers, calcium channel blockers, diuretics, nitrates, and moxisylyte) will also cause an additive hypotensive effect when given with an alpha-blocker [<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>].</li><li><strong>Cytochrome P450 3A4 (CYP3A4) inhibitors </strong>— potent CYP3A4 inhibitors (such as clarithromycin, itraconazole, and ritonavir) are predicted to moderately increase the exposure to tamsulosin, alfuzosin, and doxazosin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">BNF 76, 2018</a>].<ul><li>Concurrent use should be done cautiously, or avoided. </li><li>Terazosin is not metabolized by this enzyme and is therefore not expected to interact with CYP3A4 inhibitors.</li></ul></li></ul></li><li><strong>For a complete list of possible drug interactions of alpha-blockers, </strong>see the <a data-hyperlink-id=\"40ec65d5-2d3d-46c6-a3a8-a98f01110425\" href=\"http://scribe.clarity.co.uk/www.medicines.org.uk/emc\">electronic Medicines Compendium</a> (eMC) or the <a data-hyperlink-id=\"cf6a8caf-9ccd-4adf-9777-a98f0111044b\" href=\"https://bnf.nice.org.uk/\">British National Formulary</a> (BNF).</li></ul><!-- end field 3a635b95-4489-4e7c-9279-fd175306a5c3 --><!-- end item 4390b049-bc38-47a7-9d59-f720d6409928 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}